HOMEPPL
29.9.2021 00:03:09 CEST | Business Wire | Press release
Spotahome , the Spanish-based residential platform which manages 200,000 properties in 29 different countries across Europe, has signed an agreement with UK-based tenant due diligence and guarantee firm Homeppl to provide its landlords with a tenant referencing and guarantor service for its medium and long-term lets.
With the world opening-up and embracing a post-pandemic life, demand for both medium and long-term rentals has tripled, so being able to approve tenants quickly is imperative. But the risk of tenant fraud remains high, so it is vital that landlords have secure tenant referencing systems in place.
Homeppl’s solution combines fraud detection tests, behavioural analysis and financial algorithms, as well as Open Banking data, to assess the true transactional ability of consumers from all over Europe. It has a 0% default rate, and Homeppl is so confident in its referencing solution that it also offers guarantid - a service where it acts as a guarantor for tenants it approves - giving landlords more protection and tenants more freedom.
Spotahome has embedded the Homeppl tenant and guarantor services in a new premium package for its landlords; 2,000 have already signed up in Spotahome Premium service, with numbers expected to reach 10,000 by the end of the year.
Through this partnership with Homeppl, Spotahome - already a pioneer in digital rental due to its innovative virtual tours - is further transforming the rental process in Europe making it easier for tenants to rent and safer for landlords. Thanks to Homeppl’s service, Spotahome is reducing entry barriers to rent for tenants by no longer having to charge an initial payment of between one and three months’ rent, while also providing financial and legal security to landlords by mitigating fraud, guaranteeing rent and covering the cost of any damage to property.
CEO and Co-founder of Spotahome, Alejandro Artacho said: “ This new service offered to “Premium Spotahome Landlords” in partnership with Homeppl, makes Spotahome the only platform offering rentals with no deposit and Landlords guaranteed across multiple countries in Europe and it is just a step towards making rentals more accessible, and at the same time more secure for both tenants and landlords. In the following months, Spotahome will continue to launch new functionalities becoming the European digital rental platform of reference.
CEO of Homeppl Alexander Siedes said: “With a post-COVID recovery underway, we’re delighted that Spotahome – one of the biggest online rental firms in the world – has chosen us as their tenant referencing and tenant guarantor provider. This partnership will help support rental mobility across Europe, enabling tenants to explore new cities and rent with greater freedom while protecting landlords from any financial or legal risk.”
ENDS
About Homeppl:
Homeppl creates financial inclusion. The tech for good business brings equality of opportunity to consumers of financial and property products. This allows businesses to safely transact with more consumers, including those who have been living outside the UK, are self-employed or students, and other people without a credit file. To do this, they specialise in rental data validation, and risk assessment. So far they’ve validated 100,000+ people from 80+ countries with 0 default. As a result, Homeppl are confident in finding the best tenants.
Homeppl's overall aim is to let landlords and agencies assess any tenant, and guarantee rent.
For more information: www.homeppl.com
About Spotahome:
Spotahome is one of the European leading platforms created in 2014 specialized in mid-to-long term furnished accommodation.
For more information: www.spotahome.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928006038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom